CCS
ACRS icon

Crosspoint Capital Strategies’s Aclaris Therapeutics ACRS Stock Holding History

Crosspoint Capital Strategies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-295
Closed -$9K – 140
2017
Q1 		$9K Hold
295
– – 0.01% 64
2016
Q4 		$8K Buy
+295
New +$7.52K 0.01% 67

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Crosspoint Capital Strategies's ACRS Position: Q2 2017 in Review

Crosspoint Capital Strategies sold out of Aclaris Therapeutics (ACRS) in Q2 2017, closing a stake of 295 shares — an estimated $9K sold.

Crosspoint Capital Strategies first reported a position in ACRS in Q4 2016 and held it in 2 quarters. The position peaked at $9K in Q1 2017. 104 funds tracked by Wall St. Rank hold ACRS as of Q2 2017.

  • Crosspoint Capital Strategies reported no remaining Aclaris Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 295 Aclaris Therapeutics shares in Q2 2017, an estimated $9K.
  • Crosspoint Capital Strategies first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Aclaris Therapeutics position peaked at $9K in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2017, filed 1 Aug 2017.